Targeted drug trial aims to block growth of tough cancers
NCT ID NCT04439331
Summary
This study is testing a drug called defactinib for people with advanced cancers that have a specific genetic change called an NF2 mutation. The drug aims to block a protein that these cancer cells may need to grow. Researchers want to see if taking defactinib pills twice a day can shrink these tumors or stop them from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ECOG-ACRIN Cancer Research Group
Philadelphia, Pennsylvania, 19103, United States
Conditions
Explore the condition pages connected to this study.